Inhibition of human immunodeficiency virus type 1 replication by a bioavailable serine/threonine kinase inhibitor, fasudil hydrochloride

AIDS Research and Human Retroviruses

Volumn 14, Issue 4, 1998, Pages 293-298

  Sato, Tsuneo ^a,b   Asamitsu, Kaori ^a   Yang, Jian Ping ^a   Takahashi, Naoko ^a   Tetsuka, Toshifumi ^a   Yoneyama, Akihiko ^a   Kanagawa, Akitaka ^a,b   Okamoto, Takashi ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b ASAHI CHEMICAL INDUSTRY CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; ANTIGEN P24; FASUDIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MYOSIN LIGHT CHAIN KINASE; N (2 AMINOETHYL) 5 ISOQUINOLINESULFONAMIDE; N (2 METHYLAMINOETHYL) 5 ISOQUINOLINESULFONAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MONOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0032032364     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.293     Document Type: Article

References (34)

1. Cullen BR: Regulation of human immunodeficiency virus replication. Annu Rev Microbiol 1991;45:219-250.
2. Jones KA and Peterlin BM: Control of RNA initiation and elongation at the HIV-1 promoter. Annu Sci USA 1994;63:717-743.
3. De Clercq E: Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev 1995;8:200-239.
4. Okamoto T: Regulatory proteins of human immunodeficiency virus and therapy. In: Anti-AIDS Drug Development: Challenges, Strategies and Prospects (Mohan P and Baba M, eds.). Harwood Academic Publishers, Chur, Switzerland, 1995, pp. 117-127.
5. Perelson AS, Neumann AU, Markowitz M, Leonard JM, and Ho DD: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586.
6. Wong-Staal F: Human immunodeficiency viruses and their replication. In: Virology (Fields BN, Knipe DM, et al., eds.). Raven Press, New York, 1990, pp. 1529-1534.
7. Cullen BR and Greene WC: Functions of the auxiliary gene products of the human immunodeficiency virus type 1. Virology 1990; 178:1-5.
8. Jones KA and Peterlin BM: Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem 1994;63: 717-743.
9. Griffin GE, Leung K, Folks TM, Kunkel S, and Nabel G: Activation of HIV gene expression during monocyte differentiation by induction of NF-κB. Nature (London) 1989;339:70-73.
10. Okamoto T, Matsuyama T, Mori S, Hamamoto Y, Kobayashi N, Yamamoto N, Josephs SF, Wong-Staal F, and Shimotohno K: Augmentation of human immunodeficiency virus type 1 gene expression by tumor necrosis factor α. AIDS Res Hum Retroviruses 1989;5:131-138.
11. Siebenlist U, Franzoso G, and Brown K: Structure, regulation and function of NF-κB. Annu Rev Cell Biol 1994;10:405-455.
12. Thanos D and Maniatis T: NF-κB: A lesson in family values. Cell 1995;80:529-532.
13. Shirakawa RF and Mizel SB: In vitro activation and nuclear translocation of NF-κB catalyzed by cyclic AMP-dependent protein kinase and protein kinase C. Mol Cell Biol 1989;9:2424-2430.
14. Hayashi T, Sekine T, and Okamoto T: Identification of a new serine kinase that activates NF-κB by direct phosphorylation. J Biol Chem 1993;268:26790-26795.
15. Chen ZJ, Parent L, and Maniatis T: Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. Cell 1996;84:853-862.
16. Schwarz EM, Vanantwerp D, and Verma IM: Constitutive phosphorylation of IκBα by casein kinase II occurs preferentially at serine 293 - requirement for degradation of free IκBα. Mol Cell Biol 1996;16:3554-3559.
17. Zhong H, Yang HS, Erdjument-Bromage H, Tempst P, and Ghosh S: The transcriptional activity of NF-κB is regulated by the IκB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 1997;89:413-424.
18. Asano T, Ikegaki I, Satoh S, Suzuki Y, Shibuya M, Takayasu M, and Hidaka H; Mechanism of action of a novel antivasospasm drug, HA1077. J Pharmacol Exp Ther 1987;241:1033-1040.
19. Asano T, Suzuki T, Tsuchiya M, Satoh S, Ikegaki I, Shibuya M, Suzuki Y, and Hidaka H: Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase. Br J Pharmacol 1989;98:1091-1100.
20. Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, Nagata I, Kikuchi H, Takemae T, Hidaka H, and Nakashima M: Effect of AT877 on cerebral vasospasm after aneurysmal sub-arachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992;76:571-577.
21. Morikawa A, Sone T, and Asano T: 5-Isoquinoline-sulfonamide derivatives. Synthesis and vasodilatory activity of N-2 aminoethyl-5-isoquinoline sulfonamide derivatives. J Med Chem 1989; 32:46-50.
22. + cell model of chronic infection. J Virol 1991;65:4645-1653.
23. Folks TM, Justement J, Kinter A, Dinarello CA, and Fauci AS: Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987;238:800-802.
24. Yusa K, Oh-hara T, Tsukahara S, and Tsuruo T: Human immunodeficiency virus type 1 induces 1β-D-arabinofuranosylcytosine resistance in human H9 cell line. J Biol Chem 1992;267: 16848-16850.
25. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
26. Leung K and Nabel GJ: HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-κB-like factor. Nature (London) 1988;333:776-778.
27. Critchfield JW, Butera ST, and Folks TM: Inhibition of HIV activation in latently infected cells by flavonoid compound. AIDS Res Hum Retroviruses 1996;12:39-46.
28. Butera ST, Roberts BD, Critchfield JW, Fang G, McQuade T, Gracheck SJ, and Folks TM: Compounds that target novel cellular components involved in HIV-1 transcription. Mol Med 1995; 1:758-767.
29. Jacque JM, Fernandez B, Arenzana-Seisdedos F, Thomas D, Baleux F, Virelizier JL, and Bachelerie F: Permanent occupancy of the human immunodeficiency virus type 1 enhancer by NF-κB is needed for persistent viral replication in monocytes. J Virol 1996;70:2930-2938.
30. Seto M, Sasaki Y, Hidaka H, and Hidaka H: Effects of HA1077, a protein kinase inhibitor, on myosin phosphorylation and tension in smooth muscle. Eur J Pharmacol 1991;195:267-272.
31. Seto M, Shindo K, Ito K, and Sasaki Y: Selective inhibition of myosin phosphorylation and tension of hyperplastic arteries by the kinase inhibitor HA1077. Eur J Pharmacol 1995;276:27-33.
32. Qatsha KA, Rudolph C, Marme D, Schachtele C, and May WS: Go 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro. Proc Natl Acad Sci USA 1993;90:4674-4678.
33. Kim CH, Lim SJ, Gollapudi S, and Gupta S: Role of protein kinase C isozymes in activation of human immunodeficiency virus type 1 in chronically infected promonocytic cells: evidence against a role of PKC beta 1. Biochem Biophys Res Commun 1994; 199:292-297.
34. De Luca C, Roulston A, Koromilas A, Wainbcrg MA, and Hiscott J; Chromin human immunodeficiency viras type 1 infection of myeloid cells disrupts the autoregulatory control of the NF-κB/Rel pathway via enhanced IκBα degradation. J Virol 1996;70: 5183-5193.